Ranibizumab for neovascular age-related macular degeneration.

By P. Rosenfeld, David M. Brown, J. Heier, D. Boyer, P. Kaiser, C. Chung, R. Kim. New England Journal of Medicine, 2006

2,821 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/bde9ad1409a06e550378f5f5c3938132cb8b20f0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Adamis
2. N. Ferrara

In Ophthalmology

1. N. Ferrara
2. A. Adamis

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…neovascularization (a type of neovascularization with angiographically indistinct margins), patients receiving monthly intravitreal injections of ranibizumab experienced significantly improved visual acuity compared to sham-injected patients, even following the first treatment 207 (TABLE 2) .”
• Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective (2020, background): “The development of anti-VEGF treatments at monthly or bi-monthly intervals revolutionized the treatment of wet AMD by improving visual outcomes significantly (Brown et al., 2006; Rosenfeld et al., 2006).”